Enrollment Completed in SAFFRON Ph 3 Trial of ORPATHYS + TAGRISSO Combo in TAGRISSO-treated EGFRm, MET-overexpressed and/or amplified LA/M NSCLC patients November 10, 2025
Following discussion with FDA, safusidenib vs vorasidenib trial in grade 2 IDH1-mutant glioma cancelled November 10, 2025
DESTINY-Lung06 Ph 3 Trial of ENHERTU Initiated as 1L Therapy in Patients with HER2 Overexpressing Metastatic NonSquamous NSCLC November 4, 2025
First patient dosed in the SPaCE-MT trial of MT-302 with CAPOX with or without nivolumab or trastuzumab in 1L advanced gastroesophageal cancer November 4, 2025
Independent DSMB recommends continuation of pivotal Ph 3 study of Bria-IMT™ + immune CPI in metastatic breast cancer October 25, 2025
First Patient Enrolled in Ph 1 Trial of Tumor-Associated Antigen Cancer Vaccine EVM14 October 21, 2025
First patients enrolled in Ph 1 trial with KQB548 (BAY 3771249) in KRAS G12D-mutated tumors October 21, 2025
Ivonescimab Global Ph 3 Development Program with HARMONi-GI3 Study expanded in 1L CRC October 21, 2025
Ph 2 study of BND-22 (SAR444881) + anti-PD-1 therapy in IO-refractory NSCLC or IO-naive MSS-CRC or ovarian cancer to be initiated October 16, 2025
Initiation of Ph 1/2 study of AVZO-103 in patients with advanced solid tumors announced October 8, 2025
First Patient Enrolled in TRUST-IV Ph 3 Study of IBTROZI™ (taletrectinib) for the Adjuvant Treatment of Early-Stage ROS1+ve NSCLC October 8, 2025
Initial clinical data for BDC-4182 Ph 1 dose escalation study now expected in 3Q 2026 October 7, 2025
First patient with follicular lymphoma (FL) dosed in CELESTIAL-301 Ph 1 trial of SynKIR™-310 October 4, 2025
Investigator-Initiated Ph 1 Trial for Neoadjuvant ELI-002 7P in Pancreatic Ductal Adenocarcinoma planned September 30, 2025
THIO-101 Ph 2 trial to enroll patients in the U.S. as part of the expansion of the study in 3L treatment for advanced NSCLC September 30, 2025
ACT appointed for POLB 001 Ph 2a Trial and supply of approved bispecific antibody drug secured at no cost September 30, 2025
First patient dosed in Ph 1/2 Dose Escalation & Expansion Trial of CP-383 in Advanced Solid Tumors September 23, 2025
